Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berubicin in pediatric HGG
NCT05082493Phase 1Withdrawn
- Sponsor
- WPD Pharmaceuticals
- Start
- Dec 2023
- Primary completion
- Dec 2023
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 1, open-label, single-arm trial of berubicin in high-grade glioma (HGG), sponsored by WPD Pharmaceuticals. Primary endpoints: Maximum Tolerated Dose at 6 months, Recommended Phase 2 Dose at 6 months and 2 more. Planned start Dec 2023; status: withdrawn.
02
Drugs
berubicin
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT05082493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05082493.